ABSTRACT The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variants of concern (VOCs) and variants of interest (VOIs), compared to neutralization of the wild-type SARS-CoV-2 virus (designated D614G). Results showed minimal, statistically nonsignificant effects on neutralization titers against the B.1.1.7 (Alpha) variant (1.2-fold reduction compared with D614G); other VOCs, such as B.1.351 (Beta, including B.1.351-v1, B.1.351-v2, and B.1.351-v3), P.1 (Gamma), and B.1.617.2 (Delta), showed significantly decreased neutralization titers ranging from 2.1-fold to 8.4-fold reductions compared with D614G, although all remained susceptible to mRNA-1273-elicited serum neutralization. IMPORTANCE In light of multiple variants of SARS-CoV-2 that have been documented globally during the COVID-19 pandemic, it remains important to continually assess the ability of currently available vaccines to confer protection against newly emerging variants. Data presented herein indicate that immunization with the mRNA-1273 COVID-19 vaccine produces neutralizing antibodies against key emerging variants tested, including variants of concern and variants of interest. While the serum neutralization elicited by mRNA-1273 against most variants tested was reduced compared with that against the wild-type virus, the level of neutralization is still expected to be protective. Such data are crucial to inform ongoing and future vaccination strategies to combat COVID-19.
【저자키워드】 COVID-19, SARS-CoV-2 variants of concern, mRNA-1273, neutralization, 【초록키워드】 neutralizing antibody, SARS-CoV-2, Vaccine, coronavirus, COVID-19 vaccine, Immunity, Neutralizing antibodies, B.1.351, mRNA-1273, neutralization, COVID-19 pandemic, variant, variants of concern, Delta, B.1.617.2, SARS-CoV-2 virus, severe acute respiratory syndrome Coronavirus, virus, immunization, variants, Neutralizing activity, Transmissibility, SARS-CoV-2 variants, B.1.1.7, mRNA, P.1, sera, VOCs, Gamma, D614G, variants of interest, Beta, VOIs, respiratory, Serum Neutralization, Protective, neutralization titers, Vaccination strategy, mRNA-1273 COVID-19 vaccine, (alpha, (Beta, reduction, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, participant, wild-type SARS-CoV-2, B.1.351-v1, B.1.351-v2, fold, wild-type virus, neutralization titer, while, variants of SARS-CoV-2, Effect, susceptible, immunized, Result, tested, significantly, remained, expected, elicited, was reduced, statistically, B.1.351-v3, 【제목키워드】 SARS-CoV-2, activity,